-
Something wrong with this record ?
Recurrent pregnancy loss, plasminogen activator inhibitor-1 (-675) 4G/5G polymorphism and antiphospholipid antibodies in Czech women
I. Subrt, Z. Ulcova-Gallova, M. Cerna, M. Hejnalova, J. Slovanova, K. Bibkova, Z. Micanova,
Language English Country Denmark
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
23445116
DOI
10.1111/aji.12099
Knihovny.cz E-resources
- MeSH
- Antibodies, Antiphospholipid blood MeSH
- White People genetics MeSH
- Adult MeSH
- Gene Frequency MeSH
- Genotype MeSH
- Abortion, Habitual blood genetics immunology MeSH
- Plasminogen Activator Inhibitor 1 genetics MeSH
- Humans MeSH
- Polymorphism, Genetic MeSH
- Pregnancy MeSH
- Check Tag
- Adult MeSH
- Humans MeSH
- Pregnancy MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Geographicals
- Czech Republic MeSH
PROBLEM: This study compares the frequencies of plasminogen activator inhibitor-1 (-675) 4G/5G polymorphism and its relationship with eight antiphospholipid antibodies (aPLs) in serum of 157 patients with repeated pregnancy loss (RPL). METHOD OF STUDY: PAI-1 (-675) 4G/5G polymorphism was determined using standard PCR-RFLP method. Enzyme-linked immunosorbent assay was used for the detection of aPLs against ph-serine, ph-ethanolamine, ph-inositol, ph-DL-glycerol, phosphatidic acid, annexin V, cardiolipin, and beta2-GPI. Allelic frequency and distribution of genotypes were calculated. The prevalence of the risk conferring 4G allele and 4G/4G homozygous genotype in patients and controls was compared, and the correlation between aPLs positivity and PAI-1 4G/4G genotype was tested by chi-square test. RESULTS: Statistically highly significant correlation between RPL and PAI-1 (-675) 4G/4G genotype was found. No correlation between PAI-1 (-675) 4G/5G polymorphism and the presence of antiphospholipid antibodies in RPL patients was observed. CONCLUSIONS: PAI-1 (-675) 4G/4G homozygous genotype increases the risk of RPL independently from the aPLs positivity.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc13031576
- 003
- CZ-PrNML
- 005
- 20131003091347.0
- 007
- ta
- 008
- 131002s2013 dk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1111/aji.12099 $2 doi
- 035 __
- $a (PubMed)23445116
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a dk
- 100 1_
- $a Subrt, Ivan $u Institute of Medical Genetics, Medical Faculty, Charles University and Faculty Hospital, Pilsen, Czech Republic. subrt@fnplzen.cz
- 245 10
- $a Recurrent pregnancy loss, plasminogen activator inhibitor-1 (-675) 4G/5G polymorphism and antiphospholipid antibodies in Czech women / $c I. Subrt, Z. Ulcova-Gallova, M. Cerna, M. Hejnalova, J. Slovanova, K. Bibkova, Z. Micanova,
- 520 9_
- $a PROBLEM: This study compares the frequencies of plasminogen activator inhibitor-1 (-675) 4G/5G polymorphism and its relationship with eight antiphospholipid antibodies (aPLs) in serum of 157 patients with repeated pregnancy loss (RPL). METHOD OF STUDY: PAI-1 (-675) 4G/5G polymorphism was determined using standard PCR-RFLP method. Enzyme-linked immunosorbent assay was used for the detection of aPLs against ph-serine, ph-ethanolamine, ph-inositol, ph-DL-glycerol, phosphatidic acid, annexin V, cardiolipin, and beta2-GPI. Allelic frequency and distribution of genotypes were calculated. The prevalence of the risk conferring 4G allele and 4G/4G homozygous genotype in patients and controls was compared, and the correlation between aPLs positivity and PAI-1 4G/4G genotype was tested by chi-square test. RESULTS: Statistically highly significant correlation between RPL and PAI-1 (-675) 4G/4G genotype was found. No correlation between PAI-1 (-675) 4G/5G polymorphism and the presence of antiphospholipid antibodies in RPL patients was observed. CONCLUSIONS: PAI-1 (-675) 4G/4G homozygous genotype increases the risk of RPL independently from the aPLs positivity.
- 650 _2
- $a habituální potrat $x krev $x genetika $x imunologie $7 D000026
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a antifosfolipidové protilátky $x krev $7 D017152
- 650 _2
- $a běloši $x genetika $7 D044465
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a frekvence genu $7 D005787
- 650 _2
- $a genotyp $7 D005838
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a inhibitor aktivátoru plazminogenu 1 $x genetika $7 D017395
- 650 _2
- $a polymorfismus genetický $7 D011110
- 650 _2
- $a těhotenství $7 D011247
- 651 _2
- $a Česká republika $7 D018153
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Ulcova-Gallova, Zdenka $u -
- 700 1_
- $a Cerna, Monika $u -
- 700 1_
- $a Hejnalova, Marketa $u -
- 700 1_
- $a Slovanova, Jitka $u -
- 700 1_
- $a Bibkova, Katarina $u -
- 700 1_
- $a Micanova, Zdenka $u -
- 773 0_
- $w MED00000296 $t American journal of reproductive immunology (New York, N.Y. : 1989) $x 1600-0897 $g Roč. 70, č. 1 (2013), s. 54-8
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/23445116 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20131002 $b ABA008
- 991 __
- $a 20131003091905 $b ABA008
- 999 __
- $a ok $b bmc $g 995663 $s 830021
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2013 $b 70 $c 1 $d 54-8 $i 1600-0897 $m American journal of reproductive immunology $n Am J Reprod Immunol $x MED00000296
- LZP __
- $a Pubmed-20131002